2. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-1836.PMID:
17065651.
3. Lameris AL, Hess MW, van Kruijsbergen I, Hoenderop JG, Bindels RJ. Omeprazole enhances the colonic expression of the Mg
2+ transporter TRPM6. Pflügers Arch 2013;465:1613-1620.PMID:
23756852.
4. Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 2012;9:322-326.PMID:
22745572.
5. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012;36:405-413.PMID:
22762246.
6. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008;69:338-341.PMID:
18221401.
7. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010;56:112-116.PMID:
20189276.
8. Zipursky J, Macdonald EM, Hollands S, et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med PMID:
10.1371/journal.pmed.1001736. Published online 30 September 2014..
9. Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013;47:773-780.PMID:
23632281.
10. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011;27:180-185.PMID:
20856115.
11. Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One PMID:
10.1371/journal.pone.0112558. Published online 13 November 2014..
12. Ayuk J, Gittoes NJ. How should hypomagnesaemia be investigated and treated? Clin Endocrinol (Oxf) 2011;75:743-746.PMID:
21569071.
13. Markovits N, Loebstein R, Halkin H, et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol 2014;54:889-895.PMID:
24771616.
14. Kim S, Lee H, Park CH, et al. Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia. Am J Ther 2015;22:14-21.PMID:
23846522.
15. Dimke H, Monnens L, Hoenderop JG, Bindels RJ. Evaluation of hypomagnesemia: lessons from disorders of tubular transport. Am J Kidney Dis 2013;62:377-383.PMID:
23201160.
16. Thongon N, Krishnamra N. Apical acidity decreases inhibitory effect of omeprazole on Mg
2+ absorption and claudin-7 and -12 expression in Caco-2 monolayers. Exp Mol Med 2012;44:684-693.PMID:
22940736.
17. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003;24:47-66.PMID:
18568054.
18. Barbagallo M, Belvedere M, Dominguez LJ. Magnesium homeostasis and aging. Magnes Res 2009;22:235-246.PMID:
20228001.
19. Dorovkov MV, Ryazanov AG. Phosphorylation of annexin I by TRPM7 channel-kinase. J Biol Chem 2004;279:50643-50646.PMID:
15485879.
20. Goytain A, Quamme GA. Functional characterization of ACDP2 (ancient conserved domain protein), a divalent metal transporter. Physiol Genomics 2005;22:382-389.PMID:
15899945.
21. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002;31:166-170.PMID:
12032568.
22. Bai JP, Hausman E, Lionberger R, Zhang X. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium. Mol Pharm 2012;9:3495-3505.PMID:
23051182.
23. Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: insights from human disease. J Am Soc Nephrol 2008;19:1451-1458.PMID:
18562569.
24. Stuiver M, Lainez S, Will C, et al. CNNM2, encoding a basolateral protein required for renal Mg
2+ handling, is mutated in dominant hypomagnesemia. Am J Hum Genet 2011;88:333-343.PMID:
21397062.
25. Lameris AL, Monnens LA, Bindels RJ, Hoenderop JG. Drug-induced alterations in Mg
2+ homoeostasis. Clin Sci (Lond) 2012;123:1-14.PMID:
22409531.
26. Groenestege WM, Hoenderop JG, van den Heuvel L, Knoers N, Bindels RJ. The epithelial Mg
2+ channel transient receptor potential melastatin 6 is regulated by dietary Mg
2+ content and estrogens. J Am Soc Nephrol 2006;17:1035-1043.PMID:
16524949.
27. Novak I, Wang J, Henriksen KL, et al. Pancreatic bicarbonate secretion involves two proton pumps. J Biol Chem 2011;286:280-289.PMID:
20978133.
28. Abrams SA, Wen JP. Methodologies for using stable isotopes to assess magnesium absorption and secretion in children. J Am Coll Nutr 1999;18:30-35.PMID:
10067656.
29. Goytain A, Hines RM, El-Husseini A, Quamme GA.
NIPA1 (
SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg
2+ transporter. J Biol Chem 2007;282:8060-8068.PMID:
17166836.
30. Goytain A, Quamme GA. Identification and characterization of a novel family of membrane magnesium transporters, MMgT1 and MMgT2. Am J Physiol Cell Physiol 2008;294:C495-C502.PMID:
18057121.
31. Goytain A, Quamme GA. Functional characterization of human SLC41A1, a Mg
2+ transporter with similarity to prokaryotic MgtE Mg
2+ transporters. Physiol Genomics 2005;21:337-342.PMID:
15713785.
32. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009;151:755-756.PMID:
19920278.